Resverlogix (TSE:RVX) Hits New 1-Year Low at $0.12

Resverlogix Corp. (TSE:RVXGet Rating) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as C$0.12 and last traded at C$0.13, with a volume of 61500 shares traded. The stock had previously closed at C$0.13.

Resverlogix Stock Performance

The firm has a market cap of C$34.81 million, a price-to-earnings ratio of -13.00 and a beta of 0.51. The business has a fifty day simple moving average of C$0.16 and a 200-day simple moving average of C$0.16.

Resverlogix (TSE:RVXGet Rating) last issued its quarterly earnings results on Thursday, May 11th. The biotechnology company reported C($0.03) earnings per share for the quarter. On average, equities analysts anticipate that Resverlogix Corp. will post -0.22 earnings per share for the current year.

About Resverlogix

(Get Rating)

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.

See Also

Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with's FREE daily email newsletter.